JP2023534143A5 - - Google Patents
Info
- Publication number
- JP2023534143A5 JP2023534143A5 JP2022579737A JP2022579737A JP2023534143A5 JP 2023534143 A5 JP2023534143 A5 JP 2023534143A5 JP 2022579737 A JP2022579737 A JP 2022579737A JP 2022579737 A JP2022579737 A JP 2022579737A JP 2023534143 A5 JP2023534143 A5 JP 2023534143A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amino acid
- acid sequence
- composition according
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063042722P | 2020-06-23 | 2020-06-23 | |
| US63/042,722 | 2020-06-23 | ||
| US202063084409P | 2020-09-28 | 2020-09-28 | |
| US63/084,409 | 2020-09-28 | ||
| US202063112513P | 2020-11-11 | 2020-11-11 | |
| US63/112,513 | 2020-11-11 | ||
| US202163188141P | 2021-05-13 | 2021-05-13 | |
| US63/188,141 | 2021-05-13 | ||
| PCT/US2021/038482 WO2021262718A1 (en) | 2020-06-23 | 2021-06-22 | Actrii proteins for the treatment of pulmonary arterial hypertension (pah) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023534143A JP2023534143A (ja) | 2023-08-08 |
| JP2023534143A5 true JP2023534143A5 (https=) | 2024-07-03 |
| JP7854402B2 JP7854402B2 (ja) | 2026-05-01 |
Family
ID=79281768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022579737A Active JP7854402B2 (ja) | 2020-06-23 | 2021-06-22 | 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20230226146A1 (https=) |
| EP (1) | EP4168037A4 (https=) |
| JP (1) | JP7854402B2 (https=) |
| KR (1) | KR20230026435A (https=) |
| CN (1) | CN115989035A (https=) |
| AU (1) | AU2021296421A1 (https=) |
| BR (1) | BR112022025644A2 (https=) |
| CA (1) | CA3182838A1 (https=) |
| CL (1) | CL2022003686A1 (https=) |
| CO (1) | CO2022018719A2 (https=) |
| EC (1) | ECSP23004827A (https=) |
| IL (1) | IL299189A (https=) |
| MX (1) | MX2022016237A (https=) |
| PE (1) | PE20230783A1 (https=) |
| WO (1) | WO2021262718A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021189010A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| WO2021189019A1 (en) | 2020-03-20 | 2021-09-23 | Keros Therapeutics, Inc. | Activin receptor type ii chimeras and methods of use thereof |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| JP7854402B2 (ja) * | 2020-06-23 | 2026-05-01 | アクセルロン ファーマ インコーポレイテッド | 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質 |
| JP2025526021A (ja) * | 2022-08-10 | 2025-08-07 | ジービー００２，インコーポレイティド | 肺動脈性高血圧症（ｐａｈ）を治療するためのチロシンキナーゼ阻害剤とアクチビン２型受容体アンタゴニストの併用療法 |
| WO2024054985A2 (en) * | 2022-09-09 | 2024-03-14 | Keros Therapeutics, Inc. | Methods of administering an activin type iib variant |
| WO2024238263A1 (en) * | 2023-05-12 | 2024-11-21 | Merck Sharp & Dohme Llc | Methods of improving lung diffusion capacity in a patient with pulmonary arterial hypertension |
| EP4713372A1 (en) * | 2023-05-15 | 2026-03-25 | Immunecare Biopharmaceuticals (Shanghai) Co., Ltd | Recombinant fusion protein for treatment of pulmonary hypertension |
| WO2025122752A1 (en) * | 2023-12-07 | 2025-06-12 | Merck Sharp & Dohme Llc | Methods for treating pulmonary arterial hypertension with activin receptor type iia (actriia) proteins and/or variants thereof |
| WO2025237307A1 (zh) * | 2024-05-14 | 2025-11-20 | 苏州康宁杰瑞生物科技有限公司 | 凝血因子FXI/FXIa抑制剂用于治疗肺动脉高压和/或高血压 |
| CN120888004B (zh) * | 2025-09-30 | 2026-04-03 | 齐鲁制药有限公司 | 包含索特西普和其变体的组合物以及相关方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| CN108350057A (zh) * | 2015-05-20 | 2018-07-31 | 细胞基因公司 | 使用II型活化素受体配体阱的用于β-地中海贫血的体外细胞培养方法 |
| DK3496739T3 (da) * | 2016-07-15 | 2021-05-10 | Acceleron Pharma Inc | Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension |
| IL320014A (en) * | 2018-01-12 | 2025-06-01 | Keros Therapeutics Inc | Activin receptor type iib variants and methods of use thereof |
| KR20250133994A (ko) * | 2018-05-09 | 2025-09-09 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| JP7854402B2 (ja) * | 2020-06-23 | 2026-05-01 | アクセルロン ファーマ インコーポレイテッド | 肺動脈性肺高血圧症（ｐａｈ）の処置のためのａｃｔｒｉｉタンパク質 |
-
2021
- 2021-06-22 JP JP2022579737A patent/JP7854402B2/ja active Active
- 2021-06-22 EP EP21828310.9A patent/EP4168037A4/en active Pending
- 2021-06-22 MX MX2022016237A patent/MX2022016237A/es unknown
- 2021-06-22 PE PE2022003042A patent/PE20230783A1/es unknown
- 2021-06-22 CN CN202180051315.7A patent/CN115989035A/zh active Pending
- 2021-06-22 BR BR112022025644A patent/BR112022025644A2/pt unknown
- 2021-06-22 US US18/011,261 patent/US20230226146A1/en active Pending
- 2021-06-22 IL IL299189A patent/IL299189A/en unknown
- 2021-06-22 KR KR1020237001866A patent/KR20230026435A/ko active Pending
- 2021-06-22 AU AU2021296421A patent/AU2021296421A1/en active Pending
- 2021-06-22 CA CA3182838A patent/CA3182838A1/en active Pending
- 2021-06-22 WO PCT/US2021/038482 patent/WO2021262718A1/en not_active Ceased
-
2022
- 2022-12-21 CL CL2022003686A patent/CL2022003686A1/es unknown
- 2022-12-22 CO CONC2022/0018719A patent/CO2022018719A2/es unknown
-
2023
- 2023-01-20 EC ECSENADI20234827A patent/ECSP23004827A/es unknown
-
2024
- 2024-11-20 US US18/954,145 patent/US20250082722A1/en active Pending
-
2025
- 2025-03-14 US US19/080,516 patent/US20250249070A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023534143A5 (https=) | ||
| US20250249070A1 (en) | Actrii proteins for the treatment of pulmonary arterial hypertension (pah) | |
| US10344092B2 (en) | Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof | |
| CA2931309C (en) | Compositions and methods for treating pulmonary hypertension | |
| JP2018515088A5 (https=) | ||
| JP2017538395A5 (https=) | ||
| JP2016511752A5 (https=) | ||
| CN105658235A (zh) | 能够结合gpA33和CD3的双特异性单价双抗体及其用途 | |
| US20230192887A1 (en) | Engineered anti-her2 bispecific proteins | |
| US20220372144A1 (en) | Bi-Specific Monovalent Fc Diabodies That Are Capable of Binding CD32B and CD79b and Uses Thereof | |
| KR20240121820A (ko) | 이형이량체 릴랙신 융합체를 이용한 치료 | |
| JP2017524675A5 (https=) | ||
| CA3196112A1 (en) | Bifunctional antagonists of activin and tumor necrosis factor-alpha and uses thereof | |
| JP2023524866A (ja) | 抗ｉｌ－３３抗体の処方物 | |
| CA3221581A1 (en) | Actrii proteins and uses thereof | |
| CN111234015A (zh) | 用于延长药物半衰期的抗体、其融合蛋白和应用 | |
| US20230391880A1 (en) | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof | |
| US20230391892A1 (en) | Bifunctional antagonists of tumor necrosis factor alpha and transforming growth factor beta and uses thereof | |
| AU2021377176A1 (en) | Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof | |
| EP4351723A2 (en) | Actrii proteins and uses thereof | |
| HK1224942A1 (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof | |
| HK1224942B (en) | Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof |